{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:12:39Z","timestamp":1790161959764,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008257","name":"Tarbiat Modares University","doi-asserted-by":"publisher","award":["TMU-88-8-67"],"award-info":[{"award-number":["TMU-88-8-67"]}],"id":[{"id":"10.13039\/501100008257","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.yexcr.2012.03.004","type":"journal-article","created":{"date-parts":[[2012,3,13]],"date-time":"2012-03-13T15:48:08Z","timestamp":1331653688000},"page":"1112-1124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells"],"prefix":"10.1016","volume":"318","author":[{"given":"Fatemeh Rahimi","family":"Jamnani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Rahbarizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A.","family":"Shokrgozar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davoud","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereidoun","family":"Mahboudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Sharifzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2012.03.004_bb0005","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2009.12.002","article-title":"Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research","volume":"36","author":"Bosch","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/sj.clpt.6100449","article-title":"Advances in the treatment of breast cancer","volume":"83","author":"Moulder","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.yexcr.2012.03.004_bb0020","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/onc.2010.547","article-title":"Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth","volume":"30","author":"Emde","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.yexcr.2012.03.004_bb0025","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/1535-7163.MCT-05-0488","article-title":"Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2\/neu expressing tumors","volume":"5","author":"Helguera","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0030","unstructured":"A. Emde, W.J. Kostler, Y. Yarden, Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer, Crit. Rev. Oncol. Hematol. (in press)."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ddtec.2010.03.002","article-title":"Nanobodies\u2014from llamas to therapeutic proteins","volume":"7","author":"Kolkman","year":"2010","journal-title":"Drug Discov. Today: Technol."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0040","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.coph.2008.07.006","article-title":"Single-domain antibodies as building blocks for novel therapeutics","volume":"8","author":"Saerens","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00262-006-0180-4","article-title":"Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies","volume":"56","author":"Roovers","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcb.20536","article-title":"Recombinant polyclonal antibodies for cancer therapy","volume":"96","author":"Sharon","year":"2005","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0060","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1073\/pnas.0812059106","article-title":"Persistent elimination of ErbB-2\/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis","volume":"106","author":"Ben-Kasus","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0065","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","article-title":"Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy","volume":"28","author":"Baselga","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0070","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.molimm.2009.01.021","article-title":"Cell selection and characterization of a novel human endothelial cell specific nanobody","volume":"46","author":"Ahmadvand","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0075","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0022-1759(87)90187-6","article-title":"Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay","volume":"100","author":"Beatty","year":"1987","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.yexcr.2012.03.004_bb0080","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ijpara.2008.10.012","article-title":"Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticercosis","volume":"39","author":"Deckers","year":"2009","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0085","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/cncr.22402","article-title":"Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors","volume":"109","author":"Beckman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.yexcr.2012.03.004_bb0090","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.humimm.2010.09.007","article-title":"The state of antibody therapy","volume":"71","author":"Elbakri","year":"2010","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0095","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jim.2009.04.006","article-title":"Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma","volume":"345","author":"Jamieson","year":"2009","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.yexcr.2012.03.004_bb0100","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","article-title":"Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models","volume":"69","author":"Scheuer","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0105","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.drudis.2011.06.003","article-title":"Truncated HER2: implications for HER2-targeted therapeutics","volume":"16","author":"Zagozdzon","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.yexcr.2012.03.004_bb0110","first-page":"277","article-title":"Single domain camel antibodies: current status","volume":"74","author":"Muyldermans","year":"2001","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.antiviral.2010.05.012","article-title":"In vitro antiviral activity of single domain antibody fragments against poliovirus","volume":"87","author":"Thys","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0120","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/08820139.2010.542228","article-title":"Nanobody; an old concept and new vehicle for immunotargeting","volume":"40","author":"Rahbarizadeh","year":"2011","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0125","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/1536859041224334","article-title":"Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin","volume":"23","author":"Rahbarizadeh","year":"2004","journal-title":"Hybrid. Hybridomics"},{"key":"10.1016\/j.yexcr.2012.03.004_bb0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/hyb.2008.0079","article-title":"Anti-MUC1 nanobody can redirect T-body cytotoxic effector function","volume":"28","author":"Bakhtiari","year":"2009","journal-title":"Hybridoma (Larchmt)"},{"key":"10.1016\/j.yexcr.2012.03.004_bb0135","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jconrel.2011.06.022","article-title":"Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells","volume":"156","author":"Sadeqzadeh","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.yexcr.2012.03.004_bb0140","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1096\/fj.10-180331","article-title":"Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer","volume":"25","author":"Vaneycken","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0145","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.bbrc.2009.04.118","article-title":"A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth","volume":"384","author":"Kawa","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0150","first-page":"729","article-title":"Developing anti-HER2\/neu single-chain Fv fragments from phage display libraries","volume":"39","author":"Adams","year":"2001","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jbiotec.2009.10.010","article-title":"Isolation of antigen-binding camelid heavy chain antibody fragments (nanobodies) from an immune library displayed on the surface of Pichia pastoris","volume":"145","author":"Ryckaert","year":"2010","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0160","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1056\/NEJM199609053351008","article-title":"Phage libraries\u2014a new route to clinically useful antibodies","volume":"335","author":"Marks","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0165","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/sj.leu.2403825","article-title":"Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth","volume":"19","author":"Williams","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.yexcr.2012.03.004_bb0170","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.sbi.2010.10.002","article-title":"Protein binding specificity versus promiscuity","volume":"21","author":"Schreiber","year":"2011","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0175","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ctrv.2011.03.008","article-title":"HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer","volume":"38","author":"Tse","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0180","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/jcp.22257","article-title":"Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility","volume":"225","author":"Ghedini","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0185","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.4049\/jimmunol.166.8.5271","article-title":"Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design","volume":"166","author":"Yip","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexcr.2012.03.004_bb0190","article-title":"Diverse activities of anti-HER2 monoclonal antibodies: from growth inhibition to induction of apoptosis","volume":"39","author":"Lewis Phillips","year":"1998","journal-title":"Proc. Am. Assoc. Cancer Res"},{"key":"10.1016\/j.yexcr.2012.03.004_bb0195","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.drudis.2006.05.009","article-title":"Recombinant polyclonal antibodies: the next generation of antibody therapeutics?","volume":"11","author":"Haurum","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.yexcr.2012.03.004_bb0200","doi-asserted-by":"crossref","first-page":"13252","DOI":"10.1073\/pnas.0913476107","article-title":"Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling","volume":"107","author":"Spangler","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482712001310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482712001310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:11:51Z","timestamp":1762146711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482712001310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0014482712001310"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2012.03.004","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2012.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}